PATENT CLAIM ANALYSIS

Application Number: 15951866
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "570000"]

Abstract:
Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a N-methyl-D-aspartate (NMDA) receptor antagonist into the chamber. The methods may comprise respectively depositing a muscle relaxant, a local anesthetic into the chamber, depositing an anticonvulsant into the chamber, depositing an antidepressant into the chamber, and depositing a calcium channel blocking agent into the chamber. The methods may comprise milling the NSAID compound, the NMDA receptor antagonist, the muscle relaxant, the local anesthetic, the anticonvulsant, the antidepressant, and the calcium channel blocking agent into a powder. The methods may comprise adding a solvent with the powder and mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution and mixing the base cream and the solution to form the formulation.

Claim (Index 7):
The formulation of  claim 1 , wherein the antidepressant includes amitriptyline with a formula of C 20 H 23 N.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 91.0
- Lexical Diversity: 3.22642
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15229434', '13448088', '13328369', '10576152', '14916141']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7488443124644966
- 35 USC 102 Novelty (BERT): 0.5299044130519146
- Combined Prediction Score: 0.7269503225232384
- Mean Citation Score: 248.62927
- Max Citation Score: 336.94916
- Similarity Product: 216.56616795324803

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test